Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronchodilators for Exertional Dyspnoea in PAH
NCT02782052Phase 3Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Nebulized ipratropium bromide, Nebulized combination ipratropium bromide with salbutamol and Placebo (3 arms). Primary endpoint: Reduction of dyspnoea intensity on a Borg scale at 3 months. Planned start Jul 2016; status: withdrawn.
02
Drugs
ipratropium bromidesalbutamol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02782052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782052.